Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Therapeuticsmd Inc (NQ: TXMD ) 1.660 +0.020 (+1.22%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 7, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Therapeuticsmd Inc < Previous 1 2 Next > TherapeuticsMD Announces Second Quarter 2024 Financial Results August 12, 2024 From TherapeuticsMD, Inc. Via Business Wire TherapeuticsMD Announces First Quarter 2024 Financial Results May 10, 2024 From TherapeuticsMD, Inc. Via Business Wire TherapeuticsMD Announces Full Year 2023 Financial Results March 29, 2024 From TherapeuticsMD, Inc. Via Business Wire TherapeuticsMD Announces Third Quarter 2023 Financial Results November 14, 2023 From TherapeuticsMD, Inc. Via Business Wire TherapeuticsMD Announces Second Quarter 2023 Financial Results August 14, 2023 From TherapeuticsMD, Inc. Via Business Wire TherapeuticsMD Announces First Quarter 2023 Financial Results May 15, 2023 From TherapeuticsMD, Inc. Via Business Wire TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition April 07, 2023 From TherapeuticsMD, Inc. Via Business Wire TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma January 03, 2023 From TherapeuticsMD, Inc. Via Business Wire TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma December 04, 2022 From TherapeuticsMD, Inc. Via Business Wire TherapeuticsMD Announces Third Quarter 2022 Financial Results November 14, 2022 From TherapeuticsMD, Inc. Via Business Wire TherapeuticsMD Announces Additional $7 Million Private Placement October 31, 2022 From TherapeuticsMD, Inc. Via Business Wire TherapeuticsMD Announces $7 Million Private Placement October 03, 2022 From TherapeuticsMD, Inc. Via Business Wire TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers September 12, 2022 From TherapeuticsMD, Inc. Via Business Wire TherapeuticsMD Announces Second Quarter 2022 Financial Results August 15, 2022 From TherapeuticsMD, Inc. Via Business Wire TherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022 August 08, 2022 From TherapeuticsMD, Inc. Via Business Wire TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital August 01, 2022 From TherapeuticsMD, Inc. Via Business Wire TherapeuticsMD Announces Expiration of Tender Offer July 13, 2022 From TherapeuticsMD, Inc. Via Business Wire THERAPEUTICSMD INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TherapeuticsMD, Inc. - TXMD May 31, 2022 From Kahn Swick & Foti, LLC Via Business Wire TXMD Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of TherapeuticsMD, Inc. Is Fair to Shareholders May 31, 2022 From Halper Sadeh LLP Via Business Wire TherapeuticsMD and EW Healthcare Partners Announce Definitive Agreement for EW Healthcare Partners to acquire TherapeuticsMD May 31, 2022 From TherapeuticsMD, Inc. Via Business Wire TherapeuticsMD Receives U.S. Food and Drug Administration (FDA) Approval for Supplemental New Drug Application (sNDA) for ANNOVERA® May 20, 2022 From TherapeuticsMD, Inc. Via Business Wire TherapeuticsMD Announces First Quarter 2022 Financial Results May 16, 2022 From TherapeuticsMD, Inc. Via Business Wire TherapeuticsMD to Report First Quarter 2022 Financial Results on May 16, 2022 May 10, 2022 From TherapeuticsMD, Inc. Via Business Wire TherapeuticsMD Completes the Divestiture of vitaCare Prescription Services to GoodRx in a Cash Transaction Valued at $150 Million April 14, 2022 From TherapeuticsMD, Inc. Via Business Wire U.S. Food and Drug Administration (FDA) Responds to Request From TherapeuticsMD to Revise Certain Manufacturing Testing Limits for ANNOVERA® December 10, 2021 From TherapeuticsMD, Inc. Via Business Wire TherapeuticsMD Settles U.S. Patent Litigation with Amneal for BIJUVA® (Estradiol and Progesterone) — Allowing for a May 25, 2032 Generic Entry Date December 08, 2021 From TherapeuticsMD, Inc. Via Business Wire TherapeuticsMD Announces Third Quarter 2021 Financial Results November 11, 2021 From TherapeuticsMD, Inc. Via Business Wire TherapeuticsMD Announces Leadership Changes; Appointment of Industry Veteran, Hugh O’Dowd, as Chief Executive Officer November 11, 2021 From TherapeuticsMD, Inc. Via Business Wire TherapeuticsMD to Report Third Quarter 2021 Results on November 11, 2021 October 27, 2021 From TherapeuticsMD, Inc. Via Business Wire TherapeuticsMD Announces Appointment of Mark Glickman as Chief Business Officer October 15, 2021 From TherapeuticsMD, Inc. Via Business Wire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.